Skip to main content
SpringerLink
Log in

A Rational Approach to the Follow-up of Melanoma Patients

  • Conference paper
Cancers of the Skin

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 160))

Abstract

There are no generally accepted guidelines for the follow-up of cutaneous melanoma (CM), and there is an ongoing debate about the value of follow-up examinations. Some authors doubt whether early detection has any beneficial effect on patient survival and suggest that it may only prolong the patient’s period of suffering from the knowledge of having metastasis. A systematic review of the literature on early detection and resection of CM metastasis shows the following picture: (1) In in-transit metastasis and in regional node metastasis, the tumour volume of the metastatic nodules at the time of diagnosis is prognostically significant. Either the number of nodes involved in regional metastasis or the diameter of the largest node showed prognostic impact in different studies. Therefore, early detection seems to affect the cure rate in this stage of disease. (2) In distant metastasis, surgical resection of all recognisable metastases prolongs survival. This is true as long as only one organ system is involved and particularly if complete resection of all metastases can be achieved. Therefore, early detection contributes to prolongation of survival. We performed a follow-up study in 2008 prospectively documented consecutive patients with stage I–III cutaneous melanoma who presented for follow-up examination at the Department of Dermatology of the University of Tübingen from August 1996 to August 1998. Stage-appropriate follow-up examinations were carried out according to the German Society of Dermatology guidelines. A total of 3800 clinical examinations and 12 398 imaging techniques were documented: 62 second primary melanomas were detected in 46 patients and 233 disease recurrences in 112 patients during this time. Physical examination was responsible for the discovery of 50% of all recurrences, with the patient initially detecting the metastasis on self-examination in 17% of these cases. Technical examinations were responsible for the detection of the remaining 50%. In the primary tumour stages, 21% of all recurrences were discovered by lymph node sonography, the majority being classified as early detection. Among the recurrences, 48% were classified as early detection, and these patients had a significantly more favourable probability of recurrence-free survival than those with recurrences classified as late detection. The results of our study suggest that the follow-u schedule elaborated for cutaneous melanoma is suitable for the early detection of second primary melanomas and of early recurrences in approximately 5% patients during a 2-year follow-up period.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anonymous (1995a) Conférence de consensus. Suivi des patients opérés d’un mélanome de stade I. Ann Dermatol Venereol 122:250–258.

    Google Scholar 

  2. Anonymous (1995b) Conférence de consensus. Suivi des patients opérés d’un mélanome de stade I. Paris, France, 30 March 1995. Ann Dermatol Venereol 122:250–391.

    Google Scholar 

  3. Ardizzoni A, Grimaldi A, Repetto L, Bruzzone M, Sertoli MR, Rosso R (1987) Stage I–II melanoma: the value of metastatic work-up. Oncology 44:87–89.

    Article  PubMed  CAS  Google Scholar 

  4. Basseres N, Grob JJ, Richard MA, Thirion X, Zarour H, Noe C, Collet VA, Lota I, Bonerandi JJ (1995) Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology 191:199–203.

    Article  PubMed  CAS  Google Scholar 

  5. Berman C, Reintgen D (1993) Radiologic imaging in malignant melanoma: a review. Semin Surg Oncol 9:232–238.

    PubMed  CAS  Google Scholar 

  6. Blaheta HJ, Schittek B, Breuninger H, Maczey E, Kroeber S, Sotlar K, Ellwanger U, The-len MH, Rassner G, Bultmann B, Garbe C (1998) Lymph node micrometastases of cutaneous melanoma: increased sensitivity of molecular diagnosis in comparison to immunohistochemistry Int J Cancer 79:318–323.

    Article  PubMed  CAS  Google Scholar 

  7. Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G (1995) Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol 131:1394–1398.

    CAS  Google Scholar 

  8. Blum A, Dill-Miiller D (1998) Ultrasound of lymph nodes and the subcutis in dermatology. Hautarzt 49:942–949.

    Article  PubMed  CAS  Google Scholar 

  9. Buzaid AC, Sandler AB, Mani S, Curtis AM, Poo WJ, Bolognia JL, Ariyan S (1993) Role of computed tomography in the staging of primary melanoma. J Clin Oncol 11:638–643.

    PubMed  CAS  Google Scholar 

  10. Buzaid AC, Tinoco L, Ross MI, Legha SS, Benjamin RS (1995) Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 13:2104–2108.

    PubMed  CAS  Google Scholar 

  11. Curry BJ, Smith MJ, Hersey P (1996) Detection and quantitation of melanoma cells in the circulation of patients. Melanoma Res 6:45–54.

    Article  PubMed  CAS  Google Scholar 

  12. Curry BJ, Myers K, Hersey P (1998) Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 16:1760–1769.

    PubMed  CAS  Google Scholar 

  13. Farthmann B, Eberle J, Krasagakis K, Gstottner M, Wang N, Bisson S, Orfanos CE (1998) RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J Invest Dermatol 110:263–267.

    Article  PubMed  CAS  Google Scholar 

  14. Finck SJ, Giuliano AE, Morton DL (1983) LDH and melanoma. Cancer 51:840–843.

    Article  PubMed  CAS  Google Scholar 

  15. Garbe C (1996) Verlangertes Überleben bei fernmetastasiertem Melanom und der Einfluss von Behandlungen: Analyse des Krankheitsverlaufs von 22 Patienten mit einer Überlebenszeit von zwei Jahren und langer. Hautarzt 47:35–43.

    Article  PubMed  CAS  Google Scholar 

  16. Garbe C (1997) Epidemiologic des Hautkrebses. In: Garbe C, Dummer R, Kaufmann R, Tilgen W (eds) Dermatologische Onkologie. Springer, Berlin, Heidelberg, New York, pp 40–56.

    Chapter  Google Scholar 

  17. Garbe C, Büttner P, Ellwanger U, Bröcker EB, Jung EG, Orfanos CE, Rassner G, Wolff HH (1995) Das Zentralregister Malignes Melanom der Deutschen Dermatologischen Gesellschaft in den Jahren 1983–1993. Epidemiologische Entwicklungen und aktuelle therapeutische Versorgung des malignen Melanoms der Haut. Hautarzt 46:683–692.

    CAS  Google Scholar 

  18. Garbe C, Reusch M, Breuninger H, Dummer R, Hauschild A, Kaufmann R, Mensing HO, Meyer, Panizzon R, Schmockel C, Schofer H, Sebastian G, Soyer HP, Sterry W, Tilgen W, Volkenandt M (1998) Diagnostische und therapeutische Standards in der dermatologischen Onkologie. Hautarzt 48 [Suppl 1]:S13–S55.

    Google Scholar 

  19. Glaser R, Rass K, Seiter S, Hauschild A, Christophers E, Tilgen W (1997) Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol 15:2818–2825.

    PubMed  CAS  Google Scholar 

  20. Goerz G, Schulte BR, Roder K, Schoppe WD, Munchhoff C, Jungblut RM (1986) Malignes Melanom. Welche Untersuchungen sind fur Staging und Verlaufskontrollen sinnvoll Dtsch Med Wochenschr 111:1230–1233.

    Article  PubMed  CAS  Google Scholar 

  21. Guo HB, Stoffel WB, Bierwirth T, Mezger J, Klingmiiller D (1995) Clinical significance of serum SI00 in metastatic malignant melanoma Eur J Cancer [A] 31:1898–1902.

    Article  Google Scholar 

  22. Haffner AC, Garbe C, Burg G, Biittner P, Orfanos CE, Rassner G (1992) The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients. Br J Cancer 66:856–861.

    Article  PubMed  CAS  Google Scholar 

  23. Hanekom GS, Johnson CA, Kidson SH (1997) An improved and combined reverse tran- scription-polymerase chain reaction assay for reliable detection of metastatic melanoma cells in peripheral blood. Melanoma Res 7:111–116.

    Article  PubMed  CAS  Google Scholar 

  24. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, Christophers E (1999) S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56:338–344.

    Article  PubMed  CAS  Google Scholar 

  25. Hauschild A, Michaelsen J, Brenner W, Rudolph P, Glaser R, Henze E, Christophers E (1999) Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 9:155–161.

    Article  PubMed  CAS  Google Scholar 

  26. Henze G, Dummer R, Joller JH, Boni R, Burg G (1997) Serum SI00 - a marker for disease monitoring in metastatic melanoma. Dermatology 194:208–212.

    Article  PubMed  CAS  Google Scholar 

  27. Huang CL, Provost N, Marghoob AA, Kopf AW, Levin L, Bart RS (1998) Laboratory tests and imaging studies in patients with cutaneous malignant melanoma. J Am Acad Dermatol 39:451–463.

    Article  PubMed  CAS  Google Scholar 

  28. Iscoe N, Kersey P, Gapski J, Osoba D, From L, DeBoer G, Quirt I (1987) Predictive value of staging investigations in patients with clinical stage I malignant melanoma. Plast Reconstr Surg 80:233–239.

    Article  PubMed  CAS  Google Scholar 

  29. Kersey PA, Iscoe NA, Gapski JA, Osoba D, From L, DeBoer G, Quirt IC (1985) The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma. Br J Surg 72:614–617.

    Article  PubMed  CAS  Google Scholar 

  30. Khansur T, Sanders J, Das SK (1989) Evaluation of staging workup in malignant melanoma. Arch Surg 124:847–849.

    PubMed  CAS  Google Scholar 

  31. Kuvshinoff BW, Kurtz C, Coit DG (1997) Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 4:252–258.

    Article  PubMed  CAS  Google Scholar 

  32. National Institutes of Health (1992) Diagnosis and treatment of early melanoma. NIH Consensus Development Conference, 27–29 January 1992. Consensus Statement 10:1–25.

    Google Scholar 

  33. National Institutes of Health (1992) NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA 268:1314–1319.

    Google Scholar 

  34. Orfanos CE, Jung EG, Rassner G, Wolff HH, Garbe C (1994) Stellungnahme und Empfehlungen der Kommission malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des malignen Melanoms der Haut. Stand 1993/94. Hautarzt 45:285–291.

    Article  PubMed  CAS  Google Scholar 

  35. Prayer L, Winkelbauer H, Gritzmann N, Winkelbauer F, Helmer M, Pehamberger H (1990) Sonography versus palpation in the detection of regional lymph-node metastases in patients with malignant melanoma. Eur J Cancer 26:827–830.

    Article  PubMed  CAS  Google Scholar 

  36. Provost N, Marghoob AA, Kopf AW, DeDavid M, Wasti Q, Bart RS (1997) Laboratory tests and imaging studies in patients with cutaneous malignant melanomas: a survey of experienced physicians. J Am Acad Dermatol 36:711–720.

    Article  PubMed  CAS  Google Scholar 

  37. Rümke P, van-Everdingen JE (1992) Consensus on the management of melanoma of the skin in The Netherlands. Dutch Melanoma Working Party Eur J Cancer 28:600–604.

    Article  PubMed  Google Scholar 

  38. Rinne D, Baum RP, Hor G, Kaufmann R (1998) Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 82:1664–1671.

    Article  PubMed  CAS  Google Scholar 

  39. Salopek TG, Marghoob AA, Slade JM, Rao B, Rigel DS, Kopf AW, Bart RS (1995) An estimate of the incidence of malignant melanoma in the United States. Based on a survey of members of the American Academy of Dermatology. Dermatol Surg 21:301–305.

    CAS  Google Scholar 

  40. Schweizerische Gesellschaft fur Dermatologie und Venerologie (1993) Das primare ma- ligne Melanom der Haut. Bull Med Suisse 74:1021–1024.

    Google Scholar 

  41. Shivers SC, Wang X, Li W, Joseph E, Messina J, Glass LF, DeConti R, Cruse CW, Berman C, Fenske NA, Lyman GH, Reintgen DS (1998) Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 280:1410–1415.

    Article  PubMed  CAS  Google Scholar 

  42. Stadelmann WK, Rapaport DP, Soong SJ, Reintgen DS, Buzaid AC, Balch CM (1998) Prognostic clinical and pathologic features. In: Balch CM, Houghton AN, Sober AJ, Soong SJ (eds) Cutaneous melanoma. Quality Medical Publishing, St Louis, pp 11–50.

    Google Scholar 

  43. Steinert HC, Huch BR, Buck A, Böni R, Berthold T, Marincek B, Burg G, von-Schulthess GK (1995) Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-d-glucose Radiology 195:705–709.

    PubMed  CAS  Google Scholar 

  44. Terhune MH, Swanson N, Johnson TM (1998) Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol 134:569–572.

    Article  PubMed  CAS  Google Scholar 

  45. Wagner JD, Schauwecker D, Hutchins G, Coleman JJ (1997) Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 64:181–189.

    Article  PubMed  CAS  Google Scholar 

  46. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O’Fallon JR (1995) Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 274:1703–1705.

    Article  PubMed  CAS  Google Scholar 

  47. Wittekind C, Wagner G (1997) TNM Klassifikation maligner Tumoren, 5th edn. Springer, Berlin Heidelberg New York.

    Google Scholar 

Download references

Authors
  1. Claus Garbe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Dermatology, University of Zurich, Gloriastr. 31, 8091, Zürich, Switzerland

    Reinhard Dummer , Frank O. Nestle  & Günter Burg ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Garbe, C. (2002). A Rational Approach to the Follow-up of Melanoma Patients. In: Dummer, R., Nestle, F.O., Burg, G. (eds) Cancers of the Skin. Recent Results in Cancer Research, vol 160. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59410-6_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59410-6_24

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63969-2

  • Online ISBN: 978-3-642-59410-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation